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Independent isolates of human immunodeficiency virus (HIV) exhibit a striking genomic diversity, most of
which is located in the viral envelope gene. Since this property of the HIV group of viruses may play an
important role in the pathobiology of the virus, we analyzed the predicted amino acid sequences of the envelope
proteins of seven different HIV strains, three of which represent sequential isolates from a single patient. By
using a computer program that predicts the secondary protein structure and superimposes values for
hydrophilicity, surface probability, and flexibility, we identified several potential antigenic epitopes in the
envelope proteins of the seven different viruses. Interestingly, the majority of the predicted epitopes in the
exterior envelope protein (gpl20) were found in regions of high sequence variability which are interspersed
with highly conserved regions among the independent viral isolates. A comparison of the sequential viral
isolates revealed that changes concerning the secondary structure of the protein occurred only in regions which
were predicted to be antigenic, predominantly in highly variable regions. The membrane-associated protein
gp4l contains no highly variable regions; about 80% of the amino acids were found to be conserved, and only
one hydrophilic area was identified as likely to be accessible to antibody recognition. These findings give insight
into the secondary and possible tertiary structure of variant HIV envelope proteins and should facilitate
experimental approaches directed toward the identification and fine mapping of HIV envelope proteins.
Most patients with acquired immunodeficiency syndrome
(AIDS) or AIDS-related complex show specific antibodies
directed against proteins of human immunodeficiency virus
(HIV), which have virus-neutralizing activity (3, 37, 40, 46)
and are supposed to be directed against antigenic determi-
nants located on the surface glycoprotein, as has been shown
for other enveloped virus particles. However, the virus
seems to have adopted properties which allow evasion of the
immune surveillance mechanisms of the host. Differences
among various isolates of HIV have primarily been analyzed
at the nucleotide sequence level (35) of independent isolates
and also recently in sequential viral isolates from the same
patient (21). These variations seem to be concentrated in the
envelope protein-encoding region of HIV (20) and may be
fundamentally important for the biology and pathogenicity of
HIV (40, 50). For this reason and for the development of
viral antigens for diagnostic or vaccine use, it is important to
identify and characterize antigenic determinants located in
the glycoprotein complex of HIV and to define their possible
functions.
In this study, we analyzed the amino acid sequences of the
envelope protein complexes derived from the nucleotide
sequences of seven AIDS virus isolates (21, 36, 39, 40, 43),
three of which represented sequential isolates from the same
patient. The present work is an extension of previously
published reports on the genetic variability of the HIV
envelope protein complex, which mainly focused on the
DNA and primary amino acid sequences (9, 28, 43). By
computer analysis we predicted the secondary structure of
gpl2O and gp4l, the cleavage products of gp160 (11), and
predicted potential antigenic sites by superimposing this
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secondary structure with the values for hydrophilicity, flex-
ibility, surface probability, and glycosylation. Thus, 11 po-
tential antigenic sites were identified, 9 of which were
located in the exterior part (gpl20) of the envelope protein
and 2 in the membrane-bound portion (gp4l). Five highly
variable regions were characterized, all contained in gpl20,
coinciding with the predicted epitopes. In sequential isolates
from a single patient, all alterations of secondary structures
occurred in those regions which were identified as antigenic
epitopes.
These results indicate that genomic variations of the AIDS
virus seem to be manifested mainly in the extracellular
portion of the envelope protein. The fact that those varia-
tions coincide with possible antigenic sites suggests that
these regions may be immunogenic and may be of funda-
mental importance for the pathobiology of the virus.
MATERIALS AND METHODS
DNA and protein sequences. The following convention will
be used to designate the HIV strains used. Strains HTLV-
III(BH10), LAV(1A), HTLV-III(HAT3), HTLV-III(WMJ1),
HTLV-III(WMJ2), and HTLV-III(WMJ3) are referred to as
BH10, LAV1A, HAT3, WMJ1, WMJ2, and WMJ3, respec-
tively.
The nucleotide sequences of the envelope open reading
frames of HIV strains BH1O, LAV1A, and ARV2 have been
previously reported (36, 39, 45). HAT3 is the nucleotide
sequence of a virus isolated in 1983 from a patient with AIDS
(20, 33, 43); WMJ1 is a virus isolate from a child with AIDS
born in 1982 and infected perinatally by her HIV-positive
mother. WMJ2 and WMJ3 are sequential isolates from this
same patient taken 3 (WMJ2) and 7 (WMJ3) months after the
first (21).
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FIG. 1. Amino acid sequences of the entire envelope genes of seven HIV isolates. WMJ1, WMJ2, and WMJ3 are sequential isolates from
the same patient; BH1O, ARV2, LAV1A, and HAT3 represent independent virus isolates. Alignment of the sequences was done with the
assistance of PRTLAN (49). Numbering of amino acid sequences is done from the first residue of the envelope protein open reading frame
of WMJ1 up to the end. Dashes indicate amino acid identity with WMJ1, spaces indicate the absence of that amino acid. N-glycosylation sites
are indicated as shaded areas, amino acids in P-turn regions are encircled. Symbols: *, cysteine residues; -, conserved regions;
variable regions.
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Computer analysis of the sequences. The computer pro-
gram of Queen and Korn (34) was used for translating
nucleotide sequences into amino acids. Alignment of the
deduced amino acid sequences of the surface glycoproteins
of the seven viral isolates was accomplished with the com-
puter program PRTALN (49). The secondary structure of
the envelope proteins was predicted by a computer program
written for a VAX750, based on suggestions by Cohen et al.
(8) by using the algorithms of Chou and Fasman (6) or
Garnier et al. (16). These predictions were superimposed
with local hydrophilicity values (23). As an alternative to
hydrophilicity, the values for surface probability (modified
from Emini et al. [13]) or flexibility (24) were superimposed.
For Chou-Fasman calculations, the probability of the occur-
rence of a-helixes, 1-pleated sheets, 1-turn regions, and
random coil structures were evaluated by using stringent
conditions: Pboundary 2 1, with Pp > P and Pt > Pa (Pp =
probability for 13-sheet, Pa = probability for a-helical region,
and Pt = probability for ,B-turn regions).
The parameters were averaged over five amino acid resi-
dues with a limit of 0.7 for hydrophilicity, 5.0 for surface
probability, and 1.040 for flexibility. 1-Turn regions adjacent
to 1-sheets or at-helical regions in a hydrophilic or nonhydro-
phobic environment combined with the simultaneous occur-
rence of high values for flexibility and surface probability in
those regions were considered to be candidates for potential
antigenicity. These structures are believed to form freely
accessible and mobile loops at the protein surface and are
thus considered to be prime candidates for antigenic sites (2,
6, 12, 23, 28, 47).
RESULTS
Comparison of amino acid sequences. The open reading
frames of the envelope gene derived from the nucleotide
sequence of the seven virus isolates are similar in size and
encode 854 (WMJ3) to 873 (HAT3) amino acids (Fig. 1).
Methionine codons at positions 8 (BH1O and LAV1A) or 9
(HAT3, ARV2, WMJ1, WMJ2, and WMJ3) supposedly mark
the beginning of the envelope protein with a potential leader
sequence, which is cleaved from the envelope precursor
protein during maturation (1). The peptide sequences from
position 38 represent the envelope precursor gpl60, which is
cleaved into the exterior gp120 (with 23 to 25 potential
N-glycosylation sites) and the membrane-bound gp41 (con-
taining 4 to 7 potential N-glycosylation sites). A stretch of
positively charged amino acids at positions 510, 509, 508
(WMJ1, WMJ2, WMJ3), 517 (ARV2), 518 (BH10), 523
(LAV1A), and 527 (HAT3), respectively, marks the cleavage
site (1, 11).
Although the overall sizes and structures of the seven
surface proteins are rather similar, the deduced amino acid
sequences differ substantially. On the average only 66% of
the amino acids are conserved in the exterior part of the
protein, and these changes are clustered in special regions
with only up to 10% conserved amino acids. gp4l, the
transmembrane part of the envelope protein complex, shows
more than 80% conserved amino acids (Fig. 1, Table 1) and
no regions of high variability. Furthermore, the changes in
the latter region are all due to point mutations, whereas
changes in gpi20 frequently result from insertions and dele-
tions and appear as clustered mutations interspersed with
segments which have a high content of conserved amino
acids (89%).
According to their content of conserved amino acids,
glycosylation sites, and 13-turn regions, the envelope pro-
teins of HIV were subdivided into highly variable and
constant regions. Constant regions were defined to contain
75% or more conserved amino acids and to have no amino
acid insertions and deletions. In contrast, variable regions
showed a low degree of conserved residues (25% or less) and
a great variability in length due to deletions or insertions;
these changes occurred at at least every fifth amino acid.
Due to the high number of conserved amino acid residues
in the constant regions, glycosylation sites and secondary
structures also showed a low degree of variation; more than
50% of potential glycosylation sites and amino acids in
1-turn configurations were found to be conserved. Regions
of high variability had a low degree of conserved 13-turns (0
to 25%), especially in a hydrophilic environment, and almost
no conserved potential glycosylation sites (0 to 25%).
By these criteria, surface glycoprotein gpl60 could be
subdivided into a clustered pattern of highly variable (Vi to
V5) and constant regions (Cl to C6). For purposes of
classification the minimum length of a region was set at 10
amino acid residues; the locations and parameters of those
regions are shown in Fig. 1 and 2 and Table 1.
Prediction of antigenic determinants. (i) Exterior envelope
protein gpl20. For further analysis we predicted antigenic
determinants in the amino acid sequences with a computer
program which predicted the secondary structure and calcu-
lated the values for hydrophilicity, flexibility, and surface
probability (Fig. 2, Table 1). These regions are mainly
located in 13-turn regions which show a high degree of
nonhydrophobic or flexible amino acid sequences or are
predicted to have a high probability of location at the surface
of the polypeptide (8, 12, 13, 19, 32, 44).
In gpl20, nine epitopes (I to IX) with a high antigenic
potential can be predicted (Table 2, Fig. 2). Epitope I is
located in a region of high variability (V1) at amino acids 137
to 154 of viral strain WMJ1. The locations of the antigenic
epitopes for the other isolates are indicated in Table 2.
Epitope I has elevated values for hydrophilicity and
flexibility, 1 to 3 potential glycosylation sites, and a number
(up to 11 in LAV1A) of amino acids in 13-turn configurations.
Isolates WMJ1 and WMJ3 show no 13-turns due to the high
variability of this region. Epitope II (amino acids 186 to 203)
is situated in variable region V2 and contains residues with
high values for hydrophilicity, flexibility, and surface prob-
ability; up to 15 amino acids (HAT3) have 13-turn configura-
tions (with the exception of ARV2), and all strains may be
glycosylated. Epitope III (amino acids 232 to 246) in con-
stant region C2 shows two conserved hydrophilic 1-turns,
two conserved potential glycosylation sites, and high values
of flexibility. Epitope IV (amino acids 300 to 320) in variable
region V3 shows 2 to 8 amino acids in 13-turns, with elevated
values for hydrophilicity, flexibility, and surface probability,
and has 1 to 2 potential glycosylation sites. Epitope V (amino
acids 358 to 375) is only slightly variable (72% conserved
amino acids), has high values for hydrophilicity, surface
probability, and flexibility, and has 1 to 2 N-glycosylation
sites and 6 to 8 residues in 13-turn configurations. Epitope VI
(amino acids 394 to 412), in contrast, is in highly variable
region V4, with 2 to 4 possible glycosylation sites, 4 to 11
13-turns, and high values for hydrophilicity and flexibility; the
values for surface probability are not elevated. Epitope VII
(amino acids 445 to 458) in constant region C3 has 4 to 7
13-turns. One glycosylation site is hydrophilic and flexible
and is directly followed by epitope VIII (amino acids 459 to
469), which shows high variability (V5), is hydrophilic,
flexible, and possibly glycosylated, and has one (ARV2) to
six residues in 1-turn configurations. Epitope IX (amino
J. VIROL.
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FIG. 2. Chou-Fasman prediction of the envelope protein gp160 derived from the sequence of WMJ1. The computer plots start at the
methionine at residue 9 of the open reading frame. The probability of the occurrence of a-helices (), p-pleated sheets (-), random coils
(-), and p-turn regions ( i ) were evaluated by using stringent conditions. The parameters for hydrophilicity, flexibility, and surface
probability were averaged over five amino acid residues, with a limit of 0.7 for hydrophilicity, 1.040 for flexibility, and 5.0 for surface
probability. Symbols: 9-, N-glycosylation sites; , conserved regions; , variable regions. (A) Secondary structures superimposed with
the values for hydrophilicity; 0, hydrophilic regions, O, hydrophobic regions. (B) Secondary structures superimposed with the values for
flexibility; 0, flexible regions. (C) Secondary structures superimposed with the values for surface probability; 0, high surface probability.
acids 470 to 483) in region C4 has high values for all
parameters, four conserved ,-turns, and no potential
glycosylation sites. In fact, epitopes VII to IX are one
continuous antigenic region which is subdivided because
constant regions C3 and C4 are interrupted by V5, a rather
short region with high variability.
There may be additional epitopes in singular virus isolates
(e.g., amino acids 285 to 293 in ARV2) which were not
classified because similar epitopes could not be found in the
other virus strains.
Some of these epitopes must be considered of lesser
antigenic quality, since they have only a few p-turns (epitope
VOL. 61, 1987
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TABLE 1. Parameters and values for conserved and variable regions, calculated from the sequences of seven HIV envelope
proteins (gp 160)'
Amino Conserved amino Conserved glyco- Conserved
Region Length acid acids Glycosylation sylation sites ,3-Turns 13-turnsdeletions! sites
insertions No. % No. S No. %
C1 97/97/97 0 84 87 1/1/1 1 100 4/4/4 2 50
38-134 97/97/97/97 1/1/1/1 2/4/2/4
Vi 20/20/20 0-15 3 10 2/2/2 0 0 0/2/0 0 0
135-154 24/23/29/25 1/2/3/3 8/5/11/7
8/8/8 0 7 87 1/1/1 1 100 0/0/0 0 100
155-162 8/8/8/8 1/1/1/1 0/0/0/0
V2 41/41/41 0-18 11 21 2/3/2 1 20 5/6/5 0 0
163-203 39/44/39/52 2/4/3/5 2/2/2/17
C2 76/76/76 0 68 89 3/3/3 2 50 2/2/2 2 50
204-279 76/76/76/76 4/3/4/3 2/4/2/4
25/25/25 0 19 76 3/3/3 3 100 0/0/0 0 0
280-304 25/25/25/25 3/3/3/3 0/3/0/0
V3 26/26/26 0-5 7 25 0/0/0 0 0 4/2/4 2 25
305-330 27/26/27/26 1/1/1/1 8/6/8/8
65/65/65 0-1 48 72 5/6/6 4 67 11/9/10 8 72
331-395 66/66/66/65 5/5/5/6 11/10/11/10
V4 19/19/19 0-11 4 17 3/2/3 0 0 4/6/4 0 0
396-414 23/18/23/19 2/1/2/3 11/4/11/9
C3 44/44/44 0 38 86 1/1/1 1 100 7/7/7 4 57
415-458 44/44/44/44 1/1/1/1 7/7/7/4
V5 11/11/11 0-2 2 16 1/1/1 0 0 5//5 1 18
459-469 11/12/11/12 1/1/1/1 5/1/6/1
C4 41/41/41 0 36 87 0/0/0 0 100 4/4/4 4 100
470-510 41/41/41/41 0/0/0/0 4/4/4/4
C5 106/106/106 0-1 95 90 2/2/2 2 100 6/8/8 6 75
511-616 105/106/105/106 2/2/2/2 6/6/6/8
38/38/38 0 17 44 2/2/2 2 100 2/0/0 0 0
616-653 38/38/38/38 2/2/2/2 2/0/2/2
C6 92/92/92 0 84 85 0/0/1 0 0 6/6/6 6 66
654-745 92/92/92/92 1/0/1/0 6/8/6/10
111/111/111 0 77 69 0/0/0 0 0 5//5 4 57
746-856 111/111/11/111 2/1/2/2 5/4/5/7
III) or no high values for surface probability (epitopes I, VI,
VII, and VIII).
(ii) Transmembrane protein gp4l. Only two antigenic sites
could be identified in gp4l. These contain amino acids 612 to
635 and 722 to 745 (Fig. 1 and 2, Tables 1 and 2). The first,
epitope X, is located in a slightly variable region (56%
conserved amino acids) and contains four conserved
glycosylation sites, has high values for hydrophilicity, sur-
face probability, and flexibility, has 4 to 6 n-turns, and is
probably the only antigenic site in gp4l which is located
outside the lipid bilayer and accessible to antibody reaction
and recognition. The second epitope (amino acids 722 to 745)
is located directly after a stretch of hydrophobic amino acids
which is likely to be a transmembrane region of gp4l (TM3);
these hydrophilic, flexible amino acids in ,8-turn regions with
high surface probability probably represent the hydrophilic
anchor sequence which has been identified in most mem-
brane proteins (10). This region, however, should be inside
the cell and thus is not the best epitope for antigenic
response. The following stretch of about 100 amino acids has
a further region which might be an antigenic determinant.
This region, whose function is not known, might however be
gradually cleaved off by proteases from the precursor before
maturation of gp4l. With antibodies against a synthetic
peptide derived from this region (25), mainly the precursor
gpl60 could be identified; furthermore, the molecular size of
a glycosylated gp4l should be about 52,000 to 54,000 daltons
by calculation (42,000 daltons of the primary product plus
the molecular size of the carbohydrate moiety) unless it is
proteolytically processed.
Alterations in the envelope proteins of the sequential iso-
lates. The envelope proteins of the sequential viral isolates
from the same patient which were taken at intervals of 3 and
4 months are very similar in size and show only three amino
acid deletions or insertions. Most changes are due to point
mutations (21). Most of the alterations in the amino acid
sequences which are due to those mutations are located in
those regions which were found to be highly variable.
Differences in the secondary structures (Fig. 1) were identi-
fied in regions Vi, V2, V3, and V4, corresponding with
antigenic epitopes I, II, IV, and VI, and in epitopes V and X,
which are located in slightly variable regions (76 and 56% of
conserved amino acids, respectively). A further p-turn alter-
ation occurs in region C5 in a short hydrophilic environment
which may be located between two transmembrane-span-
ning regions (Fig. 1, 2, and 3). That means that all alterations
concerning the secondary structure of the envelope protein,
with the exception of that in region C5, are located in the
predicted antigenic determinants; epitopes III, VII, VIII,
IX, and XI are conserved. Interestingly, some of the ,B-turn
alterations identified in isolates WMJ1 and WMJ2 are re-
versed in isolate WMJ3 (I, II, IV, and VI), even if there are
further variations in the amino acid sequence (I and IV).
Prediction of tertiary structures. After cleavage of the
leader peptide from precursor protein gpl60, gpl20 repre-
sents the highly glycosylated exterior part of the envelope
J. VIROL.
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TABLE l-(Continued)
Conserved
Hydrophilic hydrophilic Hydrophilicity Surface probability Flexibility
Region Length n-turns P-turns
No. % No. % No. % No. %
C1 97/97/97 2/2/2 2 100 10/8/ 7-10 7/7/9 7-10 11/1/11 8-10
38-134 97/97/97/97 2/2/2/2 8/9/9/9 8/9/7/10 11/11/8/12
Vi 20/20/20 0/0/0 0 0 5/5/7 13-33 0/0/0 0-13 6/7/6 28-82
135-154 24/23/29/25 3/0/1/0 9/9/4/4 2/3/3/0 14/19/17/14
8/8/8 0/0/0 0 100 0/0/0 0 0/0/0 0 0/0/0 0
8/8/8/8 0/0/0/0 0/0/0/0 0/0/0/0 0/0/0/0
V2 41/41/41 4/4/4 0 0 9/17/6 14-41 9/12/4 10-32 8/11/12 20-46
163-203 39/44/39/52 2/0/2/3 7/9/7/9 5/5/5/12 11/9/11/24
C2 76/6/76 2/2/2 2 67 9/8/9 7-11 0/0/0 0 5/5/5 7-11
204-279 76/76/76/76 2/3/2/2 5/5/5/9 0/0/0/0 7/8/9/6
25/25/25 0/0/0 0 0 5/5/5 8-20 0/0/0 0 2/2/2 8-12
280-304 25/25/25/25 0/2/0/0 2/2/2/4 0/0/0/0 0/3/0/2
V3 26/26/26 3/1/3 1 16 7/5/8 19-34 2/5/5 7-22 5/0/3 0-57
305-330 27/36/27/26 6/7/6/4 717/79 6/2/6/3 12/8/12/15
65/65/65 4/4/4 4 57 11/11/11 12-17 5/5/5 6-8 8/8/9 12-25
331-395 66/66/66/65 6/7/6/4 11/8/9/10 5/5/4/4 17/10/10/10
V4 19/19/19 1/4/1 0 0 517/ 2-11 0/0/0 0-6 9/13/9 10-20
396-414 23/18/23/19 8/2/6/3 3/4/3/1 0/1/0/0 12/712113
C3 44/44/44 4/4/4 4 100 0/1/0 0-11 0/0/0 0 5/5/5 5-11
415-458 44/44/44/44 4/4/4/4 2/3/5/2 0/0/0/0 5/2/5/4
V5 11/11/11 2/2/2 0 0 10/10/10 1-90 4/5/5 0-45 10/6/10 54-100
459-469 11/12/11/12 1/0/1/0 8/2/1/7 0/0/0/1 11/9/9/11
C4 41/41/41 4/4/4 4 100 12/12/12 29-32 18/19/19 43-46 12/11/12 24-29
470-510 41/41/41/41 4/4/4/4 13/13/13/12 19/19/19/19 12/12/12/10
C5 106/106/106 0/0/0 0 100 5//5 5 8/8/8 5-7 5/s/5 6
511-616 105/106/105/106 0/0/0/0 5//5/5 8/8/8/5 6/5/6/5
38/38/38 0/0/0 0 0 7/5/5 13-23 4/4/4 10-13 3/3/3 7-10
616-653 38/38/38/38 2/0/2/2 715/74 3/4/3/4 3/3/3/2
C6 92/92/92 6/6/6 6 67 34/34/34 34 29/20/23 20-29 35/35/36 32-40
654-745 92/92/92/92 6/8/6/10 34/34/34/34 19/22/24/28 33/32/37/40
111/111/111 5/5/5 2 39 20/20/19 15-18 13/13/13 10-12 9/9/9 7-10
746-856 111/111/111/111 51215/ 20/17/20/20 12/12/12/11 10/8/10/11
aValues are arranged in the following mode: WMJ1/ WMJ2/WMJ3
BH10/ ARV2/ LAVlA/HAT3.
protein complex of HIV. This polypeptide part is likely against a direct involvement of disulfite bonds in the com-
connected only via the ionic interactions of 14 positively plex formation of gp120 and gp4l (17).
charged amino acids in the carboxy-terminal region of gp120 The transmembrane polypeptide gp41 contains three
(region C4) adjacent to the cleavage site with the negatively stretches of hydrophobic amino acids. Directly after the
charged phosphate groups in the bilayer membrane. There cleavage site there are about 60 hydrophobic residues (amino
are 18 conserved cysteine residues dispersed over the gpl20 acids 511 to 571) which are interrupted by a stretch of about
sequence (Fig. 1) which might also be involved in the 10 amino acids that are predicted to have a high surface
complex formation of gpl20 and gp4l. A report describing probability and, in comparison with the surrounding resi-
the frequent loss of gpl20 from the particles during purifica- dues, a higher hydrophilicity and flexibility and some alter-
tion and immunoelectron microscopy argues, however, ations in ,-turns. From the patterns of other viral (22, 32) or
TABLE 2. Antigenic epitopes in the various strains
Epitope R Amino acid residues in virus strain:
no. wMJ1 WMJ2 WMJ3 BH10 ARV2 LAVlA HAT3
I Vi 137-154 137-154 137-153 137-157 137-158 137-163 137-158
II V2 186-203 186-203 185-202 188-203 189-209 195-209 189-217
III C2 232-246 232-246 228-245 232-246 240-253 240-253 249-261
IV V3 300-320 300-319 299-318 300-321 300-327 308-328 316-355
V 358-375 257-374 356-373 360-377 367-384 367-384 375-391
VI V4 394-412 393-411 392-410 397-418 404-420 404-425 410-427
VII C3 445-458 444-457 443-456 451-464 453-466 457-470 459-472
VIII V5 459-469 458-468 457-467 465-475 467-478 471-481 473-484
IX C4 470-483 469-482 468-481 476-489 478-492 482-496 485-499
X 611-637 610-636 609-635 616-643 620-646 623-649 627-653
XI C6 724-745 723-744 722-743 729-750 733-754 736-757 740-761
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membrane proteins, e.g., bacteriorhodopsin (14), acetylcho-
line receptor (15), and erythrocyte band III (26), such
regions are known to represent sequential transmembrane-
spanning regions (TM1 and TM2 [Fig. 3]). A domain of
hydrophilic, flexible, and charged amino acids (amino acids
to 572 to 594) linked to the hydrophobic region may repre-
sent a hydrophilic anchor sequence.
Transmembrane region TM3, which was suggested from
amino acids 670 to 695, with its hydrophilic anchor has
already been mentioned. In transmembrane regions TM2
and TM3 three charged amino acids (arginine at positions
557 and 707 and glutamic acid at position 560) are identifi-
able. Those charged amino acids were also reported in other
transmembrane regions in multi-spanning proteins and do
not lead to disturbance of the overall hydrophobic character
of a transmembrane region (48). Between TM2 and TM3
hydrophobic regions from the N terminus of gp4l are 90
amino acid residues (580 to 670) which should be facing the
outer side of the lipid bilayer. Within this region are four
conserved glycosylation sites and a good antigenic probabil-
ity (epitope X). These considerations were combined into a
three-dimensional model of the HIV envelope protein com-
plex (Fig. 3). Alternatively, TM1 and TM2 may represent an
apolar hydrophobic stretch of amino acids located outside
the viral membrane and may play a role similar to the
paramyxovirus fusion protein by penetrating into the mem-
brane of the fusion partner (31). The same could occur if the
C-terminal part of gp4l, including or not including TM3,
O-N COOH
FIG. 3. Suggestion for the tertiary structure of envelope protein
gpl60 beginning at amino acid 38. Each circle represents one amino
acid residue, shaded areas indicate transmembrane-spanning re-
gions. Variable regions are indicated. 0, Polar amino acids; arrows,
N-glycosylation sites; , cysteine residues.
would be directed to the outer membrane or be in equilib-
rium between those two orientations. This possibility is
supported by the observation that antiserum against a pep-
tide from amino acids 725 to 752 gives cell surface labeling
and is neutralizing (Sa). The predicted antigenic determi-
nants are not affected by the discussed models.
DISCUSSION
Previous studies have shown that variability in the
genomes of different HIV isolates is a prominent feature of
this group of viruses (21, 40, 43, 50). In the present study we
analyzed the deduced amino acid sequences of seven HIV
isolates and predicted the secondary structures in combina-
tion with the values for hydrophilicity, flexibility, and sur-
face probability, which resulted in the identification of
potentially antigenic epitopes.
Analysis of the primary and secondary structure of poly-
peptide shows that antigenic determinants are often found in
loop like structures on the surface of a molecule that have
been identified as biologically important regions in several
other viral membrane or capsid proteins (8, 12, 19, 28, 30, 32,
47). Antigenic sites formed by the folding of the amino acid
chain to tertiary structures contribute to immunological
activities; this cannot be predicted by calculations similar to
those applied here. By our methods, 11 epitopes could be
identified and characterized in the envelope protein complex
of HIV, 9 of which are located in the exterior protein gp120.
A comparison of the amino acid sequences of the seven viral
strains led to the subdivision of gpl20 into highly variable
and conserved regions. Five highly variable regions could be
identified, all of which coincided with the predicted epitopes
I, II, IV, VI, and VIII. These epitopes, due to their concen-
tration of 3-turns and hydrophilic amino acids, have a very
high potential for antigenicity. Genomic variation primarily
occurs in the exterior envelope sequences and corresponds
to predicted epitopes of different AIDS virus strains, which
differ also in sequential isolates from the same patient
(epitopes I, II, IV, and VI), suggesting that immune selection
may play an important role in the generation of variant virus
strains. Two related retroviruses, equine infectious anemia
virus and visna virus (18, 41, 42), show similar progressive
changes in their envelope genes. There is evidence that these
changes do, in fact, lead to substantial changes in the
antigenic properties of the envelope which may reflect
immune selective pressure exerted by the host (7, 29, 38).
Whereas the variable regions of the exterior protein gpl20
possess properties typical for antigenic sites, the conserved
regions are generally hydrophobic and lack areas with a high
number of f-turns. There are only three exceptions: epitope
III in region C2, epitope VII in region C3, and epitope IX in
region C4. Epitope III has only two amino acids predicted in
a-turn configurations and must be considered of minor
antigenic potential, in comparison with the other epitopes.
Epitope VII shows many p-turns; these however are only
slightly hydrophilic and have no high values for surface
probability. Epitope XI in C4 (amino acids 470 to 483)
consists of a stretch of hydrophilic, flexible amino acids in
r-turn areas with high surface probability; this region is
adjacent to the cleavage site, and a synthetic peptide corre-
sponding to that region reacted with about 80% of the sera
from HIV-positive individuals (S. Modrow, unpublished
data). However, it is unclear if this epitope is conserved in
all virus strains. It is also possible that conserved region C4
might contribute to biologically important functions of the
virus particle such as virus cell adsorption and connection of
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gpl20 to the envelope membrane; both functions could
protect this region from selective immune pressure.
The highly conserved protein structures together with 18
cysteine residues conserved in the seven strains may con-
tribute to the stability of a constant core structure of gpl20,
with variable, highly antigenic regions looping out.
In contrast to the exterior protein gpl20, transmembrane
polypeptide gp4l contains no region of high variability and
consists mainly of regions with hydrophobic areas which
may be arranged into three transmembrane regions. Be-
tween these transmembrane regions is a glycosylated region
with good predicted antigenicity (epitope X), which may be
located outside the viral envelope and thus may be recog-
nized by the immune system of the host. This region has only
slight variability and may contribute to biologically impor-
tant functions as well. It thus could represent a valuable
diagnostic antigen. It has been shown (4, 5) that segments of
the protein, including epitope X, when produced as recom-
binant gene products in bacteria, are recognized by HIV-
positive sera in enzyme-linked immunosorbent assays and
Western blots; preliminary results with a synthetic peptide
from this region give similar results (Modrow, unpublished).
The last epitope, epitope XI, consists of stretches of highly
hydrophilic, flexible amino acids with high values for surface
probability and several p-turns. This region may represent
the hydrophilic anchor sequences located adjacent to
transmembrane region TM3 and thus should be located
inside the cell.
The observation that HIV binds to the CD4 molecule of T
cells (27) which is supposed to bind to molecules of the major
histocompatibility complex class II during stimulation of
immune responses may suggest functional similarities of yet
unidentified regions of gpl20 or gp4l with those of the major
histocompatibility complex class II molecules. Our analysis
of constant and variable regions may well identify candidates
for structures of dominant immunogenicity for humoral
immune response. This does not, however, exclude the
possibility that during biological degradation of viral struc-
tures other segments, including constant regions of the viral
envelope proteins, lead to formation of specific antibody
responses in patients. Such antibodies, when detected by in
vitro antigens not presented in their native configuration, can
be of diagnostic value. In addition, these antibodies may also
have neutralizing activity, since the respective sequences
recognized may be located in accessible areas of the enve-
lope or be accessible during molecular mobility.
Cellular immune mechanisms have not been addressed so
far and are not predictable by our protein analysis. How-
ever, in this case, sequential rather than complex antigens
seem to be of particular importance. Selective priming of
cell-mediated immunity with epitopes selected from detailed
analysis of the viral envelope should open new approaches
for the control of HIV-related disease.
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